

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 11, 2017**

**OPIANT PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of  
incorporation)

**000-55330**

(Commission File Number)

**46-4744124**

(IRS Employer  
Identification No.)

**401 Wilshire Blvd., 12th Floor  
Santa Monica, CA**

(Address of Principal Executive Offices)

**90401**

(Zip Code)

**(424) 252-4756**

Registrant's telephone number, including area code

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On January 11, 2017, Opiant Pharmaceuticals, Inc. (the "Company") issued a press release announcing its 2017 corporate and clinical goals which include, but are not limited to: (i) initiating a Phase 2 study in Bulimia Nervosa; (ii) continuing to provide ongoing development and intellectual property support for Adapt Pharma Limited, the Company's NARCAN® Nasal Spray commercialization partner; (iii) hiring a Chief Scientific Officer; (iv) completing an uplisting to a major stock exchange; and (v) reincorporating from Nevada to Delaware.

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.    Description

99.1            Opiant Pharmaceuticals, Inc. Press Release, dated January 11, 2017.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Opiant Pharmaceuticals, Inc.**

Date: January 18, 2017

By: /s/ Dr. Roger Crystal

Name: Dr. Roger Crystal

Title: President and Chief Executive Officer

---



### **Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals**

*- Plans to Initiate Phase 2 Study in Bulimia Nervosa -*

*- Company to Pursue Uplisting to a Major Stock Exchange -*

SANTA MONICA, Calif., Jan. 11, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced the company's 2017 corporate and clinical goals. These corporate and clinical goals include Phase 2 clinical trial initiation, ongoing support for the company's NARCAN® Nasal Spray commercialization partnership, pursuing an uplisting to a major stock exchange and senior leadership expansion.

"The recent transaction with SWK Holdings that enabled us to monetize a portion of our future NARCAN® Nasal Spray royalties significantly strengthened our balance sheet with up to \$17.5 million, and allowed us to enter 2017 well-positioned to advance development of our novel addiction treatments," said Roger Crystal, M.D., Chief Executive Officer of Opiant. "Addiction disorders represent a significant burden to society and I believe our pipeline of promising therapies can make a real difference in the lives of patients and their families. I look forward to reporting on our progress throughout 2017."

#### **2017 Clinical Goals**

During calendar year 2017, Opiant aims to achieve the following clinical development goals and milestones:

- Initiate a Phase 2 study in Bulimia Nervosa, a potentially life-threatening eating disorder with only one available FDA-approved therapy
  - Initiate an additional clinical program leveraging the FDA's 505(b)(2) regulatory pathway
  - Advance the pre-clinical research of Opiant's heroin vaccine, which was licensed in October from Walter Reed Army Institute of Research and the National Institute on Drug Abuse (NIDA)
  - Continue to support Opiant's NARCAN® Nasal Spray commercialization partner, Adapt Pharma Limited, with ongoing development and intellectual property generation
-

## 2017 Corporate Goals

During 2017, Opiant plans to achieve the following corporate goals:

- Expand the management team with the addition of a Chief Scientific Officer to oversee the expansion and advancement of Opiant's pipeline
- Pursue all necessary operating and governance requirements to complete an uplisting to a major stock exchange
- Seek shareholder approval to switch to a Delaware corporation from a Nevada corporation

"This year has the potential to be a transformational one for Opiant Pharmaceuticals," continued Dr. Crystal. "In addition to our clinical development efforts, we are taking the steps necessary to apply for listing on a major stock exchange. This could elevate visibility of our company, provide increased trading liquidity and broaden our shareholder base as we advance our pipeline of novel addiction treatments, an area of medicine in urgent need of effective new options."

Opiant will provide an update on its clinical and corporate progress for 2017 during its next conference call following the release of its fiscal second quarter financial results in March.

### **About Opiant Pharmaceuticals, Inc.**

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company's partner, Adapt Pharma Limited. For more information please visit: [www.opiant.com](http://www.opiant.com).

---

## **Forward-Looking Statements**

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

### **Corporate Contact:**

Investor.relations@opiant.com

### **Media:**

Susan Forman

DGI

[sforman@dgi.com](mailto:sforman@dgi.com)

212-825-3210

### **Investors:**

Glenn Garmont

Senior Vice President

Argot Partners

[glenn@argotpartners.com](mailto:glenn@argotpartners.com)

212-600-1902

---